- Previous Close
8.70 - Open
8.68 - Bid 8.54 x --
- Ask 8.84 x --
- Day's Range
8.58 - 8.86 - 52 Week Range
6.50 - 12.62 - Volume
1,239 - Avg. Volume
67,663 - Market Cap (intraday)
344.061M - Beta (5Y Monthly) 0.48
- PE Ratio (TTM)
-- - EPS (TTM)
-5.48 - Earnings Date Feb 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date May 6, 2022
- 1y Target Est
9.50
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics companies. Boule Diagnostics AB (publ) was founded in 1956 and is headquartered in Spånga, Sweden.
www.boule.comRecent News: BOUL.ST
View MorePerformance Overview: BOUL.ST
Trailing total returns as of 1/9/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BOUL.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BOUL.ST
View MoreValuation Measures
Market Cap
337.85M
Enterprise Value
498.95M
Trailing P/E
16.15
Forward P/E
7.19
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.61
Price/Book (mrq)
1.33
Enterprise Value/Revenue
0.89
Enterprise Value/EBITDA
12.70
Financial Highlights
Profitability and Income Statement
Profit Margin
-37.73%
Return on Assets (ttm)
-20.80%
Return on Equity (ttm)
-57.47%
Revenue (ttm)
563.33M
Net Income Avi to Common (ttm)
-212.52M
Diluted EPS (ttm)
-5.48
Balance Sheet and Cash Flow
Total Cash (mrq)
17.2M
Total Debt/Equity (mrq)
69.95%
Levered Free Cash Flow (ttm)
-160.31M